Health Canada Requests Labeling Change For All NSAIDs
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency will issue guidance to manufacturers on what risk/benefit information should be included in product labeling. Canadian advisory committee recommends uninterrupted marketing of Celebrex, reintroduction of Vioxx and continued marketing prohibition of Bextra.